...
首页> 外文期刊>Epilepsy & behavior: E&B >Efficacy and impact on cognitive functions and quality of life of perampanel as first add-on therapy in patients with epilepsy: A retrospective study
【24h】

Efficacy and impact on cognitive functions and quality of life of perampanel as first add-on therapy in patients with epilepsy: A retrospective study

机译:癫痫患者患者的第一次添加疗法和佩拉姆纳尔的疗效和影响的疗效和影响:回顾性研究

获取原文
获取原文并翻译 | 示例
   

获取外文期刊封面封底 >>

       

摘要

Cognitive dysfunctions are frequent in patients with epilepsy. This comorbidity significantly alters their quality of life and plays an important role in their therapeutic management. Perampanel is a noncompetitive antagonist of AMPA (alpha-amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid) receptors and is considered a new generation AED (antiepileptic drug) with limited impact on cognitive functions.The aims of this study were to evaluate the efficacy of perampanel as first add-on therapy and its impact on cognitive functions and quality of life in patients with epilepsy followed for 6 months at the Neurology Division of "A. Cardarelli" Hospital in Naples (Italy). (C) 2019 Elsevier Inc. All rights reserved.
机译:癫痫患者常常常见认知功能障碍。 这种合并症显着改变了他们的生活质量,并在治疗管理中发挥着重要作用。 Perampanel是AMPA(α-氨基-3-羟基-5-甲基-4-异恶唑丙醇)受体的非竞争性拮抗剂,被认为是一种新一代AED(抗癫痫药物),对认知功能有限。这项研究的目的是 为了评估Perampanel作为第一次附加治疗的疗效及其对癫痫患者的认知功能和生活质量的影响,在那不勒斯(意大利)的“A. Cardarelli”医院的神经病学划分期间为6个月。 (c)2019 Elsevier Inc.保留所有权利。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号